JPRN-UMIN000020575尚未招募未知
A prospective study of the clinical utility of immunocytochemistry in liquid-based cytology for pancreatic tumors - A prospective study of the clinical utility of ICC in LBC for pancreatic tumors
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 16years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1, Patients with serious complication in other organ. 2, Patients who have risk of bleeding. 3, Patients with pancreatic tumor which we cannot detect or puncture by EUS. 4, Patients with performance status 4. 5, Inappropriate patients for entry on this study in the judgement of the investigator.
研究者
相似试验
已完成
不适用
Prospective study of the clinical outcome of immediate and maintenance treatment of deep leg and pelvic vein thrombosis for various risk factorsI80.20I80.28DRKS00018104Hämophiliezentrum, Institut für Transfusionsmedizin, Medizinische Klinik III, Goethe Universitätsklinikum80
招募中
不适用
Investigation of clinical efficacy and safety of intramuscular administration of autologous total IgG therapy in patients with chronic urticariaDiseases of the skin and subcutaneous tissueKCT0006814Ajou University Hospital24
进行中（未招募）
1 期
Efficacy and tolerability clinical trial of BUCCALIN in the prophylaxis of respiratory infections.Episodes classified by upper respiratory infections (otitis, tonsillitis, sinusitis, pharyngotonsillitis, nasopharyngitis) and lower respiratory tract (bronchitis, pneumonia).MedDRA version: 14.1 Level: PT Classification code 10060693 Term: Respiratory tract infection bacterial System Organ Class: 10021881 - Infections and infestationsEUCTR2011-005187-25-ITSOCIETA' LABORATORIO FARMACEUTICO S.I.T. SR180
尚未招募
不适用
Clinical trial of Iron supplement in anemic pregnant women.CTRI/2022/11/047376Generex Pharmassist Pvt. Ltd.
进行中（未招募）
1 期
Clinical study assessing safety and efficacy of Istaroxime in patients affected by acute cardiac insufficiency decompensated. Five centres will be involved. Each patient will receive, in a casual order, one of the two Istaroxime dosages or placebo and therefore there will be three different treatment groups. Nor the patients neither the doctors will know the treatment received/administered.EUCTR2013-000540-26-ITCVie Therapeutics Company Limited120